AAH09218.2
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
ENO1 protein, partial
NCBI Official Synonym Full Names
enolase 1, (alpha)
NCBI Protein Information
alpha-enolase; c-myc promoter-binding protein-1; enolase-alpha; tau-crystallin; non-neural enolase; alpha enolase like 1; phosphopyruvate hydratase; plasminogen-binding protein; MYC promoter-binding protein 1; 2-phospho-D-glycerate hydro-lyase
UniProt Protein Name
Alpha-enolase
UniProt Synonym Protein Names
2-phospho-D-glycerate hydro-lyase; C-myc promoter-binding protein; Enolase 1; MBP-1; MPB-1; Non-neural enolase; NNE; Phosphopyruvate hydratase; Plasminogen-binding protein
UniProt Synonym Gene Names
UniProt Entry Name
ENOA_HUMAN
NCBI Summary for ENO1
This gene encodes alpha-enolase, one of three enolase isoenzymes found in mammals. Each isoenzyme is a homodimer composed of 2 alpha, 2 gamma, or 2 beta subunits, and functions as a glycolytic enzyme. Alpha-enolase in addition, functions as a structural lens protein (tau-crystallin) in the monomeric form. Alternative splicing of this gene results in a shorter isoform that has been shown to bind to the c-myc promoter and function as a tumor suppressor. Several pseudogenes have been identified, including one on the long arm of chromosome 1. Alpha-enolase has also been identified as an autoantigen in Hashimoto encephalopathy. [provided by RefSeq, Jan 2011]
UniProt Comments for ENO1
Function: Multifunctional enzyme that, as well as its role in glycolysis, plays a part in various processes such as growth control, hypoxia tolerance and allergic responses. May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons. Stimulates immunoglobulin production. Ref.3 Ref.18 Ref.20 Ref.21 Ref.22MBP1 binds to the myc promoter and acts as a transcriptional repressor. May be a tumor suppressor. Ref.3 Ref.18 Ref.20 Ref.21 Ref.22
Catalytic activity: 2-phospho-D-glycerate = phosphoenolpyruvate + H2O. Ref.18
Cofactor: Magnesium. Required for catalysis and for stabilizing the dimer.
Pathway: Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 4/5.
Subunit structure: Mammalian enolase is composed of 3 isozyme subunits, alpha, beta and gamma, which can form homodimers or heterodimers which are cell-type and development-specific. ENO1 interacts with PLG in the neuronal plasma membrane and promotes its activation. The C-terminal lysine is required for this binding
By similarity. Ref.23 Ref.27
Subcellular location: Cytoplasm. Cell membrane. Cytoplasm › myofibril › sarcomere › M line. Note: Can translocate to the plasma membrane in either the homodimeric (alpha/alpha) or heterodimeric (alpha/gamma) form. ENO1 is localized to the M line. Ref.21Isoform MBP-1: Nucleus Ref.21.
Tissue specificity: The alpha/alpha homodimer is expressed in embryo and in most adult tissues. The alpha/beta heterodimer and the beta/beta homodimer are found in striated muscle, and the alpha/gamma heterodimer and the gamma/gamma homodimer in neurons.
Developmental stage: During ontogenesis, there is a transition from the alpha/alpha homodimer to the alpha/beta heterodimer in striated muscle cells, and to the alpha/gamma heterodimer in nerve cells.
Induction: Induced in diffuse large cell lymphoma (DLCL) after treatment with the natural biological agent, Bryo1. Up-regulated in response to enterovirus 71 (EV71) infection (at protein level). Ref.19 Ref.31
Post-translational modification: ISGylated. Ref.29 Ref.32
Miscellaneous: Used as a diagnostic marker for many tumors and, in the heterodimeric form, alpha/gamma, as a marker for hypoxic brain injury after cardiac arrest. Also marker for endometriosis. Antibodies against alpha-enolase are present in sera from patients with cancer-associated retinopathy syndrome (CAR), a progressive blinding disease which occurs in the presence of systemic tumor growth, primarily small-cell carcinoma of the lung and other malignancies. Is identified as an autoantigen in Hashimoto encephalopathy (HE) a rare autoimmune disease associated with Hashimoto thyroiditis (HT). HT is a disorder in which destructive processes overcome the potential capacity of thyroid replacement leading to hypothyroidism.
Sequence similarities: Belongs to the enolase family.
Biophysicochemical propertiespH dependence:Enolase activity is lost above pH 9.0. Immunoglobulin production stimulating activity is retained at pH 13.0. Ref.18
Sequence caution: The sequence AAA35698.1 differs from that shown. Reason: Frameshift at several positions. The sequence AAA35698.1 differs from that shown. Reason: Sequencing errors.
Product References and Citations for anti-ENO1 antibody
1. Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis.9(4):319-26 (2002). Clin Exp Metastasis. 19:319-26 (2002).2. Tu SH, Chang CC, Chen CS, Tam KW, Wang, YJ, Lee CH, Lin HW, Cheng TC, Huang CS, Chu JS, Shih NY, Chen LC, Leu SJ, Ho YS, Wu CH. Increased expression of enolase alpha in human breast cancer confers tamifer resistant in human breast cancer cells. Breast Cancer Res Treat. 121:539-53 (2010).3. Marangos PJ, Schmechel DE, Parma AM, Goodwin FK. Developmental profile of neuron-specific (NSE) and non-neuronal (NNE) enolase. Brain Res. 190:185-93 (1980).4. Smith WC, Bolch S, Dugger DR, Li,J, Esquenazi I, Arendt A, Benzenhafer D, McDowell JH. Interaction of arrestin with enolase 1 in photoreceptor. Invest Ophthalmol Vis Sci. 52:1832-40 (2011).5. Tam JP, Zavala F.J. Multiple antigen peptide. A novel approach to increase detection sensitivity of synthetic peptides in solid-phase immunoassays. J. Immunol Methods. 124:53-61 (1989).
Research Articles on ENO1
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Pathways associated with anti-ENO1 antibody
Diseases associated with anti-ENO1 antibody
Organs/Tissues associated with anti-ENO1 antibody
|